Abstract
In The Lancet Gastroenterology & Hepatology, Aurélien Marabelle and colleagues1 report the efficacy and safety of pembrolizumab in the anal squamous cell carcinoma cohort of the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study. The results are promising, showing durable antitumour activity with pembrolizumab monotherapy in a subset of patients, with objective responses observed in 12 (11%, 95% CI 6 to 18) of 112 patients and a median duration of response not being reached (range 6·0+ to 33·9+ months) after a long median follow-up (34·7 months [IQR 32·5 to 36·4]).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
